Home Cart Sign in  
Chemical Structure| 4151-80-8 Chemical Structure| 4151-80-8

Structure of 4151-80-8

Chemical Structure| 4151-80-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 4151-80-8 ]

CAS No. :4151-80-8
Formula : C12H12B2O4
M.W : 241.84
SMILES Code : OB(C1=CC=C(C2=CC=C(B(O)O)C=C2)C=C1)O
MDL No. :MFCD00151795
InChI Key :SLHKDOGTVUCXKX-UHFFFAOYSA-N
Pubchem ID :2734608

Safety of [ 4151-80-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 4151-80-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 18
Num. arom. heavy atoms 12
Fraction Csp3 0.0
Num. rotatable bonds 3
Num. H-bond acceptors 4.0
Num. H-bond donors 4.0
Molar Refractivity 71.53
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

80.92 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.36
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-1.29
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.15
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.72
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.3

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.49
Solubility 0.78 mg/ml ; 0.00322 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.66
Solubility 0.527 mg/ml ; 0.00218 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.7
Solubility 0.479 mg/ml ; 0.00198 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.81 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.05

Application In Synthesis of [ 4151-80-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 4151-80-8 ]

[ 4151-80-8 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 624-38-4 ]
  • [ 4151-80-8 ]
  • 2
  • C12H8Br2Mg2 [ No CAS ]
  • [ 4151-80-8 ]
  • 4
  • [ 4151-80-8 ]
  • [ 111-42-2 ]
  • [ 26076-51-7 ]
  • 5
  • [ 92160-61-7 ]
  • [ 4151-80-8 ]
  • [ 243465-09-0 ]
  • 6
  • [ 4151-80-8 ]
  • [ 312924-92-8 ]
  • C48H48N2S2 [ No CAS ]
  • 7
  • [ 4151-80-8 ]
  • [ 495383-59-0 ]
  • [ 495383-63-6 ]
  • 8
  • [ 4151-80-8 ]
  • [ 328249-41-8 ]
  • [ 618903-42-7 ]
  • 9
  • [ 4151-80-8 ]
  • [ 618903-41-6 ]
  • [ 618903-43-8 ]
  • 10
  • [ 4151-80-8 ]
  • C47H79BrO18 [ No CAS ]
  • C106H166O36 [ No CAS ]
  • 11
  • [ 4151-80-8 ]
  • C85H73BrN8O8 [ No CAS ]
  • C182H154N16O16 [ No CAS ]
  • 12
  • [ 5467-74-3 ]
  • [ 92-86-4 ]
  • [ 4151-80-8 ]
  • 13
  • [ 10522-47-1 ]
  • [ 4151-80-8 ]
  • [ 910231-05-9 ]
  • 14
  • [ 103862-55-1 ]
  • [ 4151-80-8 ]
  • [ 910231-06-0 ]
  • 15
  • [ 910231-23-1 ]
  • [ 4151-80-8 ]
  • C34H28N2O4 [ No CAS ]
  • 16
  • 5-bromo-8-(methoxymethoxy)-2-methylquinoline [ No CAS ]
  • [ 4151-80-8 ]
  • C36H32N2O4 [ No CAS ]
  • 17
  • [ 5419-55-6 ]
  • [ 92-86-4 ]
  • [ 4151-80-8 ]
  • 18
  • C49H47IO10 [ No CAS ]
  • [ 4151-80-8 ]
  • [(CH2C6H2(OH)(CH3))4CH2C6H2(OH)]2C6H4C6H4 [ No CAS ]
  • 19
  • [ 4151-80-8 ]
  • [ 107-21-1 ]
  • [ 135615-38-2 ]
  • 20
  • [ 4151-80-8 ]
  • [ 113999-02-3 ]
  • 4,4’-bis(5-carboethoxy-3,4-diethylpyrrol-2-yl)biphenyl [ No CAS ]
  • C46H48N2O4 [ No CAS ]
  • 21
  • [ 4877-80-9 ]
  • [ 4151-80-8 ]
  • polymer; monomer(s): 2,3,6,7,10,11-hexahydroxytriphenylene; 4,4'-biphenyldiboronic acid [ No CAS ]
  • 22
  • [ 4151-80-8 ]
  • [ 495383-64-7 ]
  • 23
  • [ 4151-80-8 ]
  • 4,4'''''-diiodo-[1,4';1',1'';4'',1''';4''',1'''';4'''',1''''']sexiphenyl-3,2',2'''',3'''''-tetraol [ No CAS ]
  • 24
  • [ 4151-80-8 ]
  • [ 243465-10-3 ]
  • 25
  • [ 4151-80-8 ]
  • [ 243465-11-4 ]
  • 26
  • [ 4151-80-8 ]
  • [ 243465-12-5 ]
  • 27
  • [ 4151-80-8 ]
  • C74H78O14 [ No CAS ]
  • 28
  • 4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenyl trifluoromethanesulfonate [ No CAS ]
  • [ 4151-80-8 ]
  • (3R,4S,3'R,4'S)-4,4'-(1,1':4',1'':4'',1'''-quaterphenyl-4,4'''-diyl)bis{1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one} [ No CAS ]
YieldReaction ConditionsOperation in experiment
42% With potassium carbonate;tetrakis(triphenylphosphine) palladium(0); In ethanol; water; toluene; for 5h;Heating / reflux; 4- {(2S, 3R)-1-(4-FLUOROPHENYL)-3-[(3S)-3-(4-FLUOROPHENYL)-3-HYDROXYPROPYL]-4- oxoazetidin-2-yl} phenyl trifluoromethanesulfonate (80.1 mg, 0.148 mmol) and tetrakis (TRIPHENYLPHOSPHINE) palladium (0) (8. 5 mg, 0.00736 mmol) were dissolved in toluene (1.0 ML). 2.0 M aqueous potassium carbonate (0.148 ML) and a solution of 4, 4'-biphenyldiboronic acid (17.9 mg, 0.074 mmol) in ethanol (0.5 mL) were added. The reaction was stirred vigorously for 5 h at refluxing temperature under a nitrogen atmosphere and then diluted with water (2.5 mL), extracted with ethyl acetate (3 X 10 mL), washed with brine (10 mL), dried over sodium sulfate, filtered, concentrated and purified by chromatography (12 g silica gel, 10% to 100% ethyl acetate-hexane) to afford (3R, 4S, 3 R, 4 S)-4, 4 -(1, 1 : 4', 1" : 4", 1" -QUATERPHENYL-4, 4" -DIYL) BIS F 1- (4- FLUOROPHENYL)-3- [ (3)-3- (4-FLUOROPHENYL)-3-HYDROXYPROPYL] AZETIDIN-2-ONE} 102 (58 mg, 42% yield) as an off-white solid. RF = 0.4, silica gel, 1: 1 ethyl ACETATE/HEXANES. NMR 1H (CDC13) 7.7-6. 9 (M, 32H), 4.7 (m, 2H), 4.6 (s, 2H), 3.2 (M, 2H), 2.1-1. 9 (M, 8H).
  • 29
  • [ 887918-07-2 ]
  • [ 4151-80-8 ]
  • 4,4'-biphenylenebis(3,6,8-triphenylpyrene) [ No CAS ]
  • 30
  • 3,6,8-tris(m-tolyl)-1-bromopyrene [ No CAS ]
  • [ 4151-80-8 ]
  • 4,4'-biphenylenebis(3,6,8-tri-m-tolylpyrene) [ No CAS ]
  • 32
  • [ 847152-22-1 ]
  • [ 4151-80-8 ]
  • Ir2(NC11H8)4((N2C10H7C6H4C6H4)2)(2+)*2PF6(1-)=[Ir2(NC11H8)4((N2C10H7C6H4C6H4)2)](PF6)2 [ No CAS ]
  • 33
  • ammonium hexafluorophosphate [ No CAS ]
  • [Ru(2,2'-bipyridine)2[4-(4'-bromophenyl)-[2,2']bipyridinyl]](PF6)2 [ No CAS ]
  • [ 4151-80-8 ]
  • (Ru(C10N2H8)2(C5NH4C5NH3(C6H4)2))2(4+)*4PF6(1-)=(Ru(C10H8N2)2(C5NH4C5NH3(C6H4)2))2(PF6)4 [ No CAS ]
  • 34
  • [ 4877-80-9 ]
  • [ 4151-80-8 ]
  • C6H3BO [ No CAS ]
  • 35
  • [ 860438-20-6 ]
  • [ 4151-80-8 ]
  • poly(5,5''''-dibromo-3'',4''-dibutyl-3',4'''-diperfluorobutyl[2,2';5',2'';5'',2''';5''',2'''']quinquethiophene-co-4,4'-biphenylbisboric acid) [ No CAS ]
YieldReaction ConditionsOperation in experiment
29% With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In water; benzene; for 24h;Heating / reflux; COMPARATIVE EXAMPLE 2Comparative Compound (B) shown below was prepared for comparison with Exemplifying compound (IV-10), a ?-conjugated compound of the present invention. The preparation process is described below.Tetrakis(triphenylphosphine)palladium (0.02 mmol) and 3 mL of an aqueous 2N sodium carbonate solution were added to a mixture liquid of 5,5-dibromo-3,4-dibutyl-3',4'-diperfluorobutyl-[2,2';5',2;5,2';5',2]quinquethiophene (1.0 mmol), 4,4'-biphenyl-bisboric acid (1.0 mmol), and 8 mL of benzene in a nitrogen atmosphere. The resulting mixture was refluxed for 24 hours. The reaction mixture was poured into a large amount of acetone to obtain a crude product. This crude product was purified by repeated reprecipitation to obtain the intended Comparative Compound (B) in a 29% yield. The obtained Comparative Compound (B) had a molecular weight of Mn: 21,300; Mw: 30,000 according to GPC measurement (solvent: chloroform).A field effect type organic transistor was prepared in the same manner as in Example 5 except that Comparative Compound (B) was used in place of Exemplifying compound (IV-10) used in Example 5. The mobility was measured in the same manner as in Example 4. The results are shown below.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 4151-80-8 ]

Organoborons

Chemical Structure| 393870-04-7

A242390 [393870-04-7]

(4'-Methyl-[1,1'-biphenyl]-4-yl)boronic acid

Similarity: 1.00

Chemical Structure| 881913-20-8

A112222 [881913-20-8]

(3-(Naphthalen-1-yl)phenyl)boronic acid

Similarity: 0.98

Chemical Structure| 491595-36-9

A173723 [491595-36-9]

(2'-Methyl-[1,1'-biphenyl]-4-yl)boronic acid

Similarity: 0.98

Chemical Structure| 870774-29-1

A247675 [870774-29-1]

(3-(Naphthalen-2-yl)phenyl)boronic acid

Similarity: 0.98

Chemical Structure| 90555-65-0

A209728 [90555-65-0]

3-Ethylphenylboronic acid

Similarity: 0.97

Aryls

Chemical Structure| 393870-04-7

A242390 [393870-04-7]

(4'-Methyl-[1,1'-biphenyl]-4-yl)boronic acid

Similarity: 1.00

Chemical Structure| 881913-20-8

A112222 [881913-20-8]

(3-(Naphthalen-1-yl)phenyl)boronic acid

Similarity: 0.98

Chemical Structure| 491595-36-9

A173723 [491595-36-9]

(2'-Methyl-[1,1'-biphenyl]-4-yl)boronic acid

Similarity: 0.98

Chemical Structure| 870774-29-1

A247675 [870774-29-1]

(3-(Naphthalen-2-yl)phenyl)boronic acid

Similarity: 0.98

Chemical Structure| 90555-65-0

A209728 [90555-65-0]

3-Ethylphenylboronic acid

Similarity: 0.97